Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

SkinHealth Systems is back in focus after the updated fair value estimate fell about 21% from US$1.69 to US$1.34, while some analysts are still pointing to a lower but intact price target of US$2.00. Bulls and bears are working from the same reset, using the revised target to argue either for patience as the story plays out or for caution around execution and competitive pressure. In the sections that follow, you will see what is driving these views and how to follow the evolving narrative around this stock.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value SkinHealth Systems.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Roth Capital keeps a Buy rating on SkinHealth Systems, signaling that despite the lower price target, the firm still sees potential for investors who are comfortable with the current risk profile.

• TD Cowen highlights that the company’s FY26 EBITDA guidance, as communicated, implies about 20% upside versus Street forecasts, which some investors may view as support for the long term story if management delivers.

🐻 Bearish Takeaways

• Roth Capital cuts its price target from US$2.50 to US$2.00 after Q1 results, and TD Cowen trims its target from US$1.65 to US$1.50, underscoring how recent performance and updated models are pressuring valuation assumptions.

• Roth Capital flags ongoing competitive pressure, especially in the lower end of the market where cheaper knock offs and scaled down devices are gaining traction with cost focused providers, raising questions about pricing power and execution.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

We’ve flagged 2 risks for SkinHealth Systems. See which could impact your investment.

How This Changes the Fair Value For SkinHealth Systems

• Fair value moves from US$1.69 to US$1.34, a reduction of roughly 21% based on the updated model.

• The revenue growth assumption is adjusted from 2.30% to 1.79%.

• The net profit margin assumption shifts from 6.16% to 8.12%.

• The future P/E multiple changes from 16.08x to 10.39x on expected earnings.

• The discount rate used in the analysis moves from 12.33% to 12.46%.

Never Miss an Update: Follow The Narrative

Narratives link a company’s story, its competitive position, and its end markets to a financial forecast and fair value. They refresh as new data, guidance, and risks emerge so you can see how the thesis is evolving in real time.